CTX-2026

N/A

Report date: 2024/10/24 14:58:57

Base Information

Drug NameCTX-2026
Drug Alias NameCTX-2026
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-Butyrophilin subfamily 3 member A1
TargetsButyrophilin subfamily 3 member A1
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCompass Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesCompass Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A